1. Home
  2. DSGN

DSGN

Design Therapeutics Inc.

Logo Design Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Founded: 2017 Country:
United States
United States
Employees: N/A City: CARLSBAD
Market Cap: 212.4M IPO Year: 2021
Target Price: $5.00 AVG Volume (30 days): 256.7K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.19 EPS Growth: N/A
52 Week Low/High: $1.94 - $8.47 Next Earning Date: 05-07-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: